ANTIBODY-CONTAINING PREPARATION

In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In a...

Full description

Saved in:
Bibliographic Details
Main Authors SASAKI, Hitoshi, MURATA, Hiroko, YAMAGUCHI, So, KAMEOKA, Daisuke, NUMATA, Megumi, HIRONIWA, NAOKA, YOSHIZAWA, Toru
Format Patent
LanguageEnglish
French
German
Published 13.12.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.
Bibliography:Application Number: EP20200889058